{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:01:21Z","timestamp":1780124481270,"version":"3.54.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03576-6","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:00:27Z","timestamp":1775725227000},"page":"2387-2407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Future Directions in the Medical Treatment of Obesity: A Narrative Review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7841-3986","authenticated-orcid":false,"given":"Aya","family":"Bassatne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3933-9461","authenticated-orcid":false,"given":"Ivania","family":"Rizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"3576_CR1","doi-asserted-by":"crossref","unstructured":"Emmerich SD FC, Stierman B, Ogden CL. Obesity and severe obesity prevalence in adults: United States, August 2021\u2013August 2023. NCHS Data Brief, no 508 Hyattsville, MD: National Center for Health Statistics. 2024.","DOI":"10.15620\/cdc\/159281"},{"issue":"4","key":"3576_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jamacardio.2018.0022","volume":"3","author":"SS Khan","year":"2018","unstructured":"Khan SS, Ning H, Wilkins JT, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3(4):280\u20137.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"3576_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1467-789X.2006.00251.x","volume":"7","author":"SC Wearing","year":"2006","unstructured":"Wearing SC, Hennig EM, Byrne NM, Steele JR, Hills AP. Musculoskeletal disorders associated with obesity: a biomechanical perspective. Obes Rev. 2006;7(3):239\u201350.","journal-title":"Obes Rev"},{"issue":"3","key":"3576_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMp068177","volume":"356","author":"P Hossain","year":"2007","unstructured":"Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world\u2014a growing challenge. N Engl J Med. 2007;356(3):213\u20135.","journal-title":"N Engl J Med"},{"issue":"8","key":"3576_CR5","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer\u2014viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794\u20138.","journal-title":"N Engl J Med"},{"issue":"10046","key":"3576_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","volume":"388","author":"E Di Angelantonio","year":"2016","unstructured":"Di Angelantonio E, Bhupathiraju SN, Wormser D, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776\u201386.","journal-title":"Lancet"},{"issue":"12","key":"3576_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49200","volume":"7","author":"KE Thorpe","year":"2024","unstructured":"Thorpe KE, Joski PJ. Estimated reduction in health care spending associated with weight loss in adults. JAMA Netw Open. 2024;7(12):e2449200-e.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"3576_CR8","first-page":"354","volume":"27","author":"J Cawley","year":"2021","unstructured":"Cawley J, Biener A, Meyerhoefer C, et al. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm. 2021;27(3):354\u201366.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"3576_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMra1514009","volume":"376","author":"SB Heymsfield","year":"2017","unstructured":"Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254\u201366.","journal-title":"N Engl J Med"},{"issue":"12","key":"3576_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.3685","volume":"5","author":"B Rader","year":"2024","unstructured":"Rader B, Hazan R, Brownstein JS. Changes in adult obesity trends in the US. JAMA Health Forum. 2024;5(12):e243685-e.","journal-title":"JAMA Health Forum"},{"issue":"1","key":"3576_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s40200-025-01604-w","volume":"24","author":"M Gholami","year":"2025","unstructured":"Gholami M, Balajam NZ, Rakhsha S, Sajjadi-Jazi SM, Shafiee G, Heshmat R. GLP-1 receptor agonists efficacy in managing comorbidities associated with diabetes mellitus: a narrative review. J Diabetes Metab Disord. 2025;24(1):92.","journal-title":"J Diabetes Metab Disord"},{"issue":"10469","key":"3576_CR12","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/S0140-6736(24)01548-4","volume":"404","author":"GBD 2021 US Obesity Forecasting Collaborators","year":"2024","unstructured":"GBD 2021 US Obesity Forecasting Collaborators. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990\u20132021, and forecasts up to 2050. Lancet. 2024;404(10469):2278\u201398.","journal-title":"Lancet"},{"issue":"25","key":"3576_CR13","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","volume":"381","author":"ZJ Ward","year":"2019","unstructured":"Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440\u201350.","journal-title":"N Engl J Med"},{"key":"3576_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101882","volume":"58","author":"M Chakhtoura","year":"2023","unstructured":"Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882.","journal-title":"EClinicalMedicine"},{"issue":"9548","key":"3576_CR15","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type\u00a02 diabetes. Lancet. 2006;368(9548):1696\u2013705.","journal-title":"Lancet"},{"issue":"3","key":"3576_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","volume":"49","author":"E Melson","year":"2025","unstructured":"Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2025;49(3):433\u201351.","journal-title":"Int J Obes (Lond)"},{"issue":"8","key":"3576_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","volume":"24","author":"DJ Drucker","year":"2025","unstructured":"Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025;24(8):631\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"3576_CR18","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s42255-024-01113-9","volume":"6","author":"JJ Holst","year":"2024","unstructured":"Holst JJ. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. Nat Metab. 2024;6(10):1866\u201385.","journal-title":"Nat Metab"},{"key":"3576_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","volume":"104","author":"L Jensen","year":"2017","unstructured":"Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31\u201341.","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"3576_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"10278","key":"3576_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et al. Semaglutide 2.4\u00a0mg once a week in adults with overweight or obesity, and type\u00a02 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase\u00a03 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"issue":"14","key":"3576_CR22","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"14","key":"3576_CR23","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"10","key":"3576_CR24","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391.","journal-title":"Nat Med"},{"issue":"3","key":"3576_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type\u00a02 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase\u00a03a trial. Lancet Diabetes Endocrinol. 2022;10(3):193\u2013206.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"3576_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","volume":"12","author":"Y Mu","year":"2024","unstructured":"Mu Y, Bao X, Eliaschewitz FG, et al. Efficacy and safety of once weekly semaglutide 2.4\u00a0mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024;12(3):184\u201395.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3576_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350.","journal-title":"JAMA"},{"issue":"11","key":"3576_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","volume":"13","author":"S Wharton","year":"2025","unstructured":"Wharton S, Freitas P, Hjelmes\u00e6th J, et al. Once-weekly semaglutide 7.2\u00a0mg in adults with obesity (STEP UP): a randomised, controlled, phase\u00a03b trial. Lancet Diabetes Endocrinol. 2025;13(11):949\u201363.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"3576_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S2213-8587(25)00141-X","volume":"13","author":"L Ji","year":"2025","unstructured":"Ji L, Gao L, Xue H, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Diabetes Endocrinol. 2025;13(9):777\u201389.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10403","key":"3576_CR30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50\u00a0mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2023;402(10403):705\u201319.","journal-title":"Lancet"},{"issue":"11","key":"3576_CR31","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25\u00a0mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077\u201387.","journal-title":"N Engl J Med"},{"issue":"18","key":"3576_CR32","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796\u2013806.","journal-title":"N Engl J Med"},{"issue":"3","key":"3576_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"key":"3576_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70106","author":"HE Bays","year":"2026","unstructured":"Bays HE, Toth P, Alkhouri N, et al. Weekly subcutaneous VK2735, a GIP\/GLP-1 receptor dual agonist, for weight management: phase\u00a02, randomized, 13-week VENTURE study. Obesity. 2026. https:\/\/doi.org\/10.1002\/oby.70106.","journal-title":"Obesity"},{"issue":"9","key":"3576_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/NEJMoa2504214","volume":"393","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, Ryan DH, Bays HE, et al. Once-monthly maridebart cafraglutide for the treatment of obesity\u2014a phase\u00a02 trial. N Engl J Med. 2025;393(9):843\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"3576_CR36","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","volume":"392","author":"L Ji","year":"2025","unstructured":"Ji L, Jiang H, Bi Y, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med. 2025;392(22):2215\u201325.","journal-title":"N Engl J Med"},{"issue":"3","key":"3576_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","volume":"12","author":"CW le Roux","year":"2024","unstructured":"le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase\u00a02 trial. Lancet Diabetes Endocrinol. 2024;12(3):162\u201373.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"3576_CR38","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al. Triple\u2013hormone-receptor agonist Retatrutide for obesity\u2014a phase\u00a02 trial. N Engl J Med. 2023;389(6):514\u201326.","journal-title":"N Engl J Med"},{"issue":"10317","key":"3576_CR39","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","volume":"398","author":"DCW Lau","year":"2021","unstructured":"Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase\u00a02 trial. Lancet. 2021;398(10317):2160\u201372.","journal-title":"Lancet"},{"key":"3576_CR40","doi-asserted-by":"crossref","unstructured":"Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase\u00a02, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631\u201343.","DOI":"10.1016\/S0140-6736(25)02155-5"},{"issue":"7","key":"3576_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2502081","volume":"393","author":"WT Garvey","year":"2025","unstructured":"Garvey WT, Bl\u00fcher M, Contreras CKO, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393(7):635\u201347.","journal-title":"N Engl J Med"},{"issue":"10499","key":"3576_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","volume":"406","author":"K Dahl","year":"2025","unstructured":"Dahl K, Toubro S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase\u00a01b\/2a randomised controlled study. Lancet. 2025;406(10499):149\u201362.","journal-title":"Lancet"},{"issue":"1","key":"3576_CR43","doi-asserted-by":"publisher","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type\u00a02 diabetes and obesity: a phase\u00a02 randomized clinical trial. JAMA Netw Open. 2021;4(1):e2033457.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"3576_CR44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima S-i, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type\u00a02 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase\u00a03a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"3576_CR45","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"19","key":"3576_CR46","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type\u00a02 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"12","key":"3576_CR47","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"10489","key":"3576_CR48","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca MP, Catarig A-M, Houlind K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type\u00a02 diabetes (STRIDE): a phase\u00a03b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580\u201393.","journal-title":"Lancet"},{"issue":"21","key":"3576_CR49","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase\u00a03 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399.","journal-title":"N Engl J Med"},{"issue":"2","key":"3576_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type\u00a02 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"17","key":"3576_CR51","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573\u201383.","journal-title":"N Engl J Med"},{"issue":"3","key":"3576_CR52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","volume":"33","author":"AM Chao","year":"2023","unstructured":"Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33(3):159\u201366.","journal-title":"Trends Cardiovasc Med"},{"issue":"11","key":"3576_CR53","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S2213-8587(25)00225-6","volume":"13","author":"I Lingvay","year":"2025","unstructured":"Lingvay I, Bergenheim SJ, Buse JB, et al. Once-weekly semaglutide 7.2\u00a0mg in adults with obesity and type\u00a02 diabetes (STEP UP T2D): a randomised, controlled, phase\u00a03b trial. Lancet Diabetes Endocrinol. 2025;13(11):935\u201348.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3576_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101762","volume":"75","author":"W Guo","year":"2023","unstructured":"Guo W, Xu Z, Zou H, et al. Discovery of ecnoglutide\u2014a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. 2023;75:101762.","journal-title":"Mol Metab"},{"issue":"9","key":"3576_CR55","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/dom.12971","volume":"19","author":"A Gummesson","year":"2017","unstructured":"Gummesson A, Nyman E, Knutsson M, Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type\u00a02 diabetes. Diabetes Obes Metab. 2017;19(9):1295\u2013305.","journal-title":"Diabetes Obes Metab"},{"key":"3576_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645507","volume":"12","author":"B Gallwitz","year":"2021","unstructured":"Gallwitz B, Giorgino F. Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol (Lausanne). 2021;12:645507.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"3576_CR57","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","volume":"60","author":"RV Overgaard","year":"2021","unstructured":"Overgaard RV, Navarria A, Ingwersen SH, B\u00e6kdal TA, Kildemoes RJ. Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials. Clin Pharmacokinet. 2021;60(10):1335\u201348.","journal-title":"Clin Pharmacokinet"},{"key":"3576_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar7047","volume":"10","author":"ST Buckley","year":"2018","unstructured":"Buckley ST, B\u00e6kdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10:467.","journal-title":"Sci Transl Med"},{"issue":"10","key":"3576_CR59","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamainternmed.2025.3599","volume":"185","author":"T Kadowaki","year":"2025","unstructured":"Kadowaki T, Heftdal LD, Ko H-J, et al. Oral semaglutide in an east asian population with overweight or obesity, with or without type\u00a02 diabetes: the OASIS 2 randomized clinical trial. JAMA Intern Med. 2025;185(10):1206\u201317.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"3576_CR60","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1111\/dom.15184","volume":"25","author":"E Pratt","year":"2023","unstructured":"Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase\u00a01a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023;25(9):2634\u201341.","journal-title":"Diabetes Obes Metab"},{"issue":"47","key":"3576_CR61","doi-asserted-by":"publisher","first-page":"29959","DOI":"10.1073\/pnas.2014879117","volume":"117","author":"T Kawai","year":"2020","unstructured":"Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci. 2020;117(47):29959\u201367.","journal-title":"Proc Natl Acad Sci"},{"key":"3576_CR62","doi-asserted-by":"crossref","unstructured":"Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type\u00a02 diabetes (ATTAIN-2): a phase\u00a03, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026;406(10522):2927\u201344.","DOI":"10.1016\/S0140-6736(25)02165-8"},{"issue":"12","key":"3576_CR63","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.2337\/db11-0979","volume":"60","author":"M Christensen","year":"2011","unstructured":"Christensen M, Vedtofte L, Holst JJ, Vilsb\u00f8ll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60(12):3103\u20139.","journal-title":"Diabetes"},{"key":"3576_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"3576_CR65","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","volume":"31","author":"RJ Samms","year":"2020","unstructured":"Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410\u201321.","journal-title":"Trends Endocrinol Metab"},{"key":"3576_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type\u00a02 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201314.","journal-title":"Mol Metab"},{"issue":"10402","key":"3576_CR67","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type\u00a02 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase\u00a03 trial. Lancet. 2023;402(10402):613\u201326.","journal-title":"Lancet"},{"issue":"11","key":"3576_CR68","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase\u00a03 trial. Nat Med. 2023;29(11):2909\u201318.","journal-title":"Nat Med"},{"issue":"1","key":"3576_CR69","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348.","journal-title":"JAMA"},{"issue":"1","key":"3576_CR70","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, Roux CWl, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336.","journal-title":"N Engl J Med"},{"issue":"10295","key":"3576_CR71","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type\u00a02 diabetes (SURPASS-1): a double-blind, randomised, phase\u00a03 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"5","key":"3576_CR72","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"4","key":"3576_CR73","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310.","journal-title":"N Engl J Med"},{"issue":"13","key":"3576_CR74","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205.","journal-title":"N Engl J Med"},{"key":"3576_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101139","volume":"46","author":"JE Campbell","year":"2021","unstructured":"Campbell JE. Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms. Mol Metab. 2021;46:101139.","journal-title":"Mol Metab"},{"issue":"2","key":"3576_CR76","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","volume":"6","author":"MM V\u00e9niant","year":"2024","unstructured":"V\u00e9niant MM, Lu S-C, Atangan L, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase\u00a01 settings. Nat Metab. 2024;6(2):290\u2013303.","journal-title":"Nat Metab"},{"issue":"3","key":"3576_CR77","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1530\/JOE-12-0368","volume":"215","author":"A Pocai","year":"2012","unstructured":"Pocai A. Unraveling oxyntomodulin, GLP1\u2019s enigmatic brother. J Endocrinol. 2012;215(3):335.","journal-title":"J Endocrinol"},{"issue":"10","key":"3576_CR78","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s00125-017-4354-8","volume":"60","author":"MA S\u00e1nchez-Garrido","year":"2017","unstructured":"S\u00e1nchez-Garrido MA, Brandt SJ, Clemmensen C, M\u00fcller TD, DiMarchi RD, Tsch\u00f6p MH. GLP-1\/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851\u201361.","journal-title":"Diabetologia"},{"key":"3576_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101691","volume":"54","author":"L Ji","year":"2022","unstructured":"Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9\u00a0mg and 10\u00a0mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase\u00a01b trial. EClinicalMedicine. 2022;54:101691.","journal-title":"EClinicalMedicine"},{"key":"3576_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105791","volume":"117","author":"W Dong","year":"2025","unstructured":"Dong W, Bai J, Yuan Q, et al. Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis. EBioMedicine. 2025;117:105791.","journal-title":"EBioMedicine"},{"key":"3576_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-10026-w","author":"D Zhu","year":"2025","unstructured":"Zhu D, Zhao J, Cai H et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature (2025). https:\/\/doi.org\/10.1038\/s41586-025-10026-w","journal-title":"Nature"},{"key":"3576_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110779","volume":"207","author":"T Klein","year":"2024","unstructured":"Klein T, Augustin R, Hennige AM. Perspectives in weight control in diabetes\u2014survodutide. Diabetes Res Clin Pract. 2024;207:110779.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"3576_CR83","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41591-025-03765-w","volume":"31","author":"B McGowan","year":"2025","unstructured":"McGowan B, Ciudin A, Baker JL, et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med. 2025;31(10):3229\u201332.","journal-title":"Nat Med"},{"issue":"9","key":"3576_CR84","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","volume":"34","author":"T Coskun","year":"2022","unstructured":"Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-47.e9.","journal-title":"Cell Metab"},{"key":"3576_CR85","unstructured":"Lilly. Lilly\u2019s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase\u00a03 trial 2025. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-weight-loss-average. Accessed 15 Dec 2025."},{"issue":"12","key":"3576_CR86","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1111\/bph.13496","volume":"173","author":"RL Bower","year":"2016","unstructured":"Bower RL, Hay DL. Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development. Br J Pharmacol. 2016;173(12):1883\u201398.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"3576_CR87","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7570\/jomes21071","volume":"30","author":"B Dehestani","year":"2021","unstructured":"Dehestani B, Stratford NR, le Roux CW. Amylin as a future obesity treatment. J Obes Metab Syndr. 2021;30(4):320\u20135.","journal-title":"J Obes Metab Syndr"},{"issue":"1","key":"3576_CR88","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/CRD.0000000000000513","volume":"32","author":"AM D\u2019Ascanio","year":"2024","unstructured":"D\u2019Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: a long-acting amylin analog for the treatment of obesity. Cardiol Rev. 2024;32(1):83\u201390.","journal-title":"Cardiol Rev"},{"issue":"15","key":"3576_CR89","doi-asserted-by":"publisher","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","volume":"64","author":"T Kruse","year":"2021","unstructured":"Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183\u201394.","journal-title":"J Med Chem"},{"key":"3576_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102271","volume":"102","author":"DA Briere","year":"2025","unstructured":"Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. Mol Metab. 2025;102:102271.","journal-title":"Mol Metab"},{"issue":"7","key":"3576_CR91","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1056\/NEJMoa2502082","volume":"393","author":"MJ Davies","year":"2025","unstructured":"Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide\u2013semaglutide in adults with overweight or obesity and type\u00a02 diabetes. N Engl J Med. 2025;393(7):648\u201359.","journal-title":"N Engl J Med"},{"key":"3576_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105862","author":"RE Kuhre","year":"2025","unstructured":"Kuhre RE, Ballar\u00edn-Gonz\u00e1lez B, Brand CL, et al. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine. 2025. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105862.","journal-title":"EBioMedicine"},{"key":"3576_CR93","doi-asserted-by":"crossref","unstructured":"Aimelet V, Holst JJ. Pharmacological intervention: challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type\u00a02 diabetes. Diabetes Obes Metab. 2026;28(2):803\u2013816.","DOI":"10.1111\/dom.70229"},{"issue":"6","key":"3576_CR94","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1515\/jbcpp-2024-0065","volume":"35","author":"M Kaur","year":"2024","unstructured":"Kaur M, Misra S. Bimagrumab: an investigational human monoclonal antibody against activin type\u00a0II receptors for treating obesity. J Basic Clin Physiol Pharmacol. 2024;35(6):325\u201334.","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"3576_CR95","unstructured":"American Diabetes Association. BELIEVE spotlights quality and quantity approach to weight management with combo therapy 2025. https:\/\/www.adameetingnews.org\/believe-spotlights-quality-and-quantity-approach-to-weight-management-with-combo-therapy\/. Accessed 15 Dec 2025."},{"issue":"14","key":"3576_CR96","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jama.2025.14392","volume":"334","author":"MJ Gonzalez-Rellan","year":"2025","unstructured":"Gonzalez-Rellan MJ, Drucker DJ. New molecules and indications for GLP-1 medicines. JAMA. 2025;334(14):1231\u20134.","journal-title":"JAMA"},{"issue":"8","key":"3576_CR97","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"3576_CR98","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/obr.12551","volume":"18","author":"GA Bray","year":"2017","unstructured":"Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715\u201323.","journal-title":"Obes Rev"},{"key":"3576_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102782","volume":"75","author":"N Alfaris","year":"2024","unstructured":"Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type\u00a02 diabetes and obesity: a narrative review. EClinicalMedicine. 2024;75:102782.","journal-title":"EClinicalMedicine"},{"key":"3576_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085304","volume":"392","author":"S West","year":"2026","unstructured":"West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304.","journal-title":"BMJ"},{"issue":"9","key":"3576_CR101","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0083","volume":"14","author":"SD Pearson","year":"2025","unstructured":"Pearson SD, Whaley CM, Emond SK. Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. J Comp Eff Res. 2025;14(9):e250083.","journal-title":"J Comp Eff Res"},{"issue":"10","key":"3576_CR102","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.4258","volume":"6","author":"A Sarpatwari","year":"2025","unstructured":"Sarpatwari A, Soto MJ, Ganguli I, Sloan CE, Goss F, Sinaiko AD. Glucagon-like peptide-1 receptor agonist order fills and out-of-pocket costs by race, ethnicity, and indication. JAMA Health Forum. 2025;6(10):e254258-e.","journal-title":"JAMA Health Forum"},{"issue":"2","key":"3576_CR103","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/1468-0009.12693","volume":"102","author":"JR Jolin","year":"2024","unstructured":"Jolin JR, Kwon M, Brock E, et al. Policy interventions to enhance medical care for people with obesity in the United States-challenges, opportunities, and future directions. Milbank Q. 2024;102(2):336\u201350.","journal-title":"Milbank Q"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03576-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03576-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03576-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:03:13Z","timestamp":1780120993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03576-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":103,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3576"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03576-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ivania Rizo reports advisory fees from Novo Nordisk and Genentech. Aya Bassatne declares no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}